CORCEPT THERAPEUTICS INC APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
CORCEPT THERAPEUTICS INC (CORT) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $2.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-06-30 was $2.73M, a 20.79% decline year-over-year.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-03-31 was $815.00K, a 62.48% decline year-over-year.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-09-30 was $2.42M, a 246.70% increase year-over-year.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-06-30 was $3.45M, a 162.48% increase year-over-year.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2025 was $9.94M, a 97.20% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2024 was $5.04M, a 371.12% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2023 was $1.07M.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.73M 10-Q · filed 2026-07-29 | $3.55M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2026-03-31 | $815.00K 10-Q · filed 2026-07-29 | |||
| 2025-12-31 | $9.94M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $2.42M 10-Q · filed 2025-11-04 | $5.87M derived: sum of 2 quarters · filed 2026-07-29 | $8.04M derived: sum of 3 quarters · filed 2026-07-29 | |
| 2025-06-30 | $3.45M 10-Q · filed 2026-07-29 | $5.62M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2025-03-31 | $2.17M 10-Q · filed 2026-07-29 | |||
| 2024-12-31 | $5.04M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $698.00K 10-Q · filed 2025-11-04 | $2.01M derived: sum of 2 quarters · filed 2025-11-04 | $3.29M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $1.31M 10-Q · filed 2025-11-04 | $2.60M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $1.28M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $1.07M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $1.07M 10-Q · filed 2024-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |